-+ 0.00%
-+ 0.00%
-+ 0.00%

ExpreS2ion Q2 FY26 net loss narrows to SEK 9.7 million; revenue climbs to SEK 11.55 million

PUBT·08/20/2026 06:35:01
Listen to the news
ExpreS2ion Q2 FY26 net loss narrows to SEK 9.7 million; revenue climbs to SEK 11.55 million
  • ExpreS2ion posted Q2 operating income of SEK 11.55 million, more than doubled from the year-earlier quarter.
  • Loss after financial items widened to SEK 11.75 million; net loss narrowed to SEK 9.7 million.
  • Cash fell to SEK 34.38 million at June 30; total assets declined to SEK 57.79 million.
  • DSMB reported no dose-limiting toxicities in ES2B-C001 Phase I; 12 of 13 evaluable patients showed anti-HER2 responses.
  • Phase I primary readout remains targeted for end-2026; DSMB recommended expanding the 450 µg cohort by three patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ExpreS2ion Biotech Holding AB published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.